Christopher Gresty

1.3k total citations · 1 hit paper
22 papers, 914 citations indexed

About

Christopher Gresty is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Genetics. According to data from OpenAlex, Christopher Gresty has authored 22 papers receiving a total of 914 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 14 papers in Pulmonary and Respiratory Medicine and 4 papers in Genetics. Recurrent topics in Christopher Gresty's work include PARP inhibition in cancer therapy (17 papers), Prostate Cancer Treatment and Research (9 papers) and Advanced Breast Cancer Therapies (5 papers). Christopher Gresty is often cited by papers focused on PARP inhibition in cancer therapy (17 papers), Prostate Cancer Treatment and Research (9 papers) and Advanced Breast Cancer Therapies (5 papers). Christopher Gresty collaborates with scholars based in United Kingdom, United States and France. Christopher Gresty's co-authors include Fred Saad, Jinyu Kang, Antoine Thiery-Vuillemin, Joseph E. Burgents, David Olmos, Neeraj Agarwal, Johann S. de Bono, Shahneen Sandhu, Guilhem Roubaud and Joaquı́n Mateo and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Christopher Gresty

22 papers receiving 911 citations

Hit Papers

Survival with Olaparib in Metastatic Castration-Resistant... 2020 2026 2022 2024 2020 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer
    2020 474 citations Maha Hussain, Joaquı́n Mateo et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Christopher Gresty United Kingdom 10 700 441 343 165 113 22 914
Weixiu Luo United States 11 659 0.9× 136 0.3× 262 0.8× 203 1.2× 175 1.5× 18 1.0k
Zachery R. Reichert United States 13 392 0.6× 389 0.9× 291 0.8× 215 1.3× 51 0.5× 55 726
Zsófia Sztupinszki Denmark 15 398 0.6× 199 0.5× 412 1.2× 234 1.4× 44 0.4× 34 691
W. Li China 11 684 1.0× 337 0.8× 372 1.1× 191 1.2× 104 0.9× 47 981
U. Matulonis United States 9 342 0.5× 252 0.6× 125 0.4× 46 0.3× 126 1.1× 33 596
Theresa Link Germany 13 501 0.7× 184 0.4× 190 0.6× 310 1.9× 101 0.9× 55 754
Salvatore Luca Burgio Italy 16 312 0.4× 594 1.3× 167 0.5× 246 1.5× 33 0.3× 40 858
Dzifa Y. Duose United States 16 170 0.2× 195 0.4× 261 0.8× 239 1.4× 29 0.3× 45 698
Frank Campana United States 19 696 1.0× 142 0.3× 537 1.6× 79 0.5× 119 1.1× 52 1.2k
Mikhail Dvorkin United States 13 746 1.1× 487 1.1× 127 0.4× 211 1.3× 153 1.4× 43 924

Countries citing papers authored by Christopher Gresty

Since Specialization
Citations

This map shows the geographic impact of Christopher Gresty's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher Gresty with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher Gresty more than expected).

Fields of papers citing papers by Christopher Gresty

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher Gresty. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher Gresty. The network helps show where Christopher Gresty may publish in the future.

Co-authorship network of co-authors of Christopher Gresty

This figure shows the co-authorship network connecting the top 25 collaborators of Christopher Gresty. A scholar is included among the top collaborators of Christopher Gresty based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher Gresty. Christopher Gresty is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Neven, Patrick, Erika Hamilton, Barbara Pistilli, et al.. (2023). 206P Capivasertib (C) + palbociclib (P) and fulvestrant (F) in patients (pts) with HR+/HER2- advanced breast cancer (ABC): Phase Ib data from CAPItello-292. ESMO Open. 8(1). 101395–101395. 2 indexed citations
4.
Crabb, Simon J., Dingwei Ye, Hirotsugu Uemura, et al.. (2023). CAPItello-280: A phase III study of capivasertib and docetaxel versus placebo and docetaxel in metastatic castration-resistant prostate cancer.. Journal of Clinical Oncology. 41(6_suppl). TPS287–TPS287. 9 indexed citations
5.
Saad, Fred, Antoine Thiery-Vuillemin, Paweł Wiechno, et al.. (2022). Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial. The Lancet Oncology. 23(10). 1297–1307. 21 indexed citations
6.
7.
Matsubara, Nobuaki, Johann S. de Bono, David Olmos, et al.. (2021). Olaparib efficacy in patients with metastatic castration-resistant prostate cancer (mCRPC) carrying circulating tumor (ct) DNA alterations in BRCA1, BRCA2 or ATM: Results from the PROfound study.. Journal of Clinical Oncology. 39(6_suppl). 27–27. 15 indexed citations
8.
Hussain, Maha, Joaquı́n Mateo, Karim Fizazi, et al.. (2020). Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer. New England Journal of Medicine. 383(24). 2345–2357. 474 indexed citations breakdown →
9.
Agarwal, Neeraj, Keith R. Abrams, Dominic Muston, et al.. (2020). 622P Exploring the impact of treatment switching on the interim overall survival (OS) results of the PROfound study. Annals of Oncology. 31. S514–S514. 1 indexed citations
10.
11.
Saad, Fred, Guilhem Roubaud, Giuseppe Procopio, et al.. (2020). Impact of olaparib vs physician’s choice of new hormonal agent (pcNHA) on burden of pain in metastatic castration-resistant prostate cancer (mCRPC): PROfound.. Journal of Clinical Oncology. 38(15_suppl). 5538–5538. 1 indexed citations
12.
Thiery-Vuillemin, Antoine, Johann S. de Bono, Fred Saad, et al.. (2020). Health-related quality of life (HRQoL) for olaparib versus enzalutamide or abiraterone in metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations: PROfound.. Journal of Clinical Oncology. 38(15_suppl). 5539–5539. 4 indexed citations
13.
Domchek, S. M., Sophie Postel‐Vinay, S-A. Im, et al.. (2019). Abstract PD5-04: An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Updated results in patients with germline BRCA-mutated (gBRCAm) metastatic breast cancer (MBC). Cancer Research. 79(4_Supplement). PD5–4. 16 indexed citations
14.
Bang, Yung‐Jue, Bella Kaufman, Ravit Geva, et al.. (2019). An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in patients with relapsed gastric cancer.. Journal of Clinical Oncology. 37(4_suppl). 140–140. 37 indexed citations
15.
Domchek, S. M., Sophie Postel‐Vinay, S-A. Im, et al.. (2019). Abstract OT3-05-03: MEDIOLA: An open-label, phase I/II basket study of olaparib (PARP inhibitor) and durvalumab (anti-PD-L1 antibody)–Additional breast cancer cohorts. Cancer Research. 79(4_Supplement). OT3–5. 6 indexed citations
16.
Drew, Yvette, Bella Kaufman, Susana Banerjee, et al.. (2019). Phase II study of olaparib + durvalumab (MEDIOLA): Updated results in germline BRCA-mutated platinum-sensitive relapsed (PSR) ovarian cancer (OC). Annals of Oncology. 30. v485–v486. 80 indexed citations
17.
Domchek, S. M., Sophie Postel‐Vinay, Y-J. Bang, et al.. (2018). Abstract PD6-11: An open-label, multitumor, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline BRCA -mutated (g BRCA m) HER2-negative metastatic breast cancer (MBC). Cancer Research. 78(4_Supplement). PD6–11. 41 indexed citations
18.
Drew, Yvette, Maja J.A. de Jonge, Sook Hee Hong, et al.. (2018). An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline BRCA -mutated ( gBRCA m) platinum-sensitive relapsed (PSR) ovarian cancer (OC). Gynecologic Oncology. 149. 246–247. 111 indexed citations
19.
Penson, Richard T., Yvette Drew, Maja J.A. de Jonge, et al.. (2018). MEDIOLA: A phase I/II trial of olaparib (PARP inhibitor) in combination with durvalumab (anti-PD-L1 antibody) in pts with advanced solid tumours – new ovarian cancer cohorts. Annals of Oncology. 29. viii147–viii147. 8 indexed citations
20.
Krebs, Matthew, Maja J.A. de Jonge, Fabrice Barlési, et al.. (2017). P1.15-004 An Open-Label, Multitumor Phase II Basket Study of Olaparib and Durvalumab (MEDIOLA): Results in Patients with Relapsed SCLC. Journal of Thoracic Oncology. 12(11). S2044–S2045. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Weixiu Luo Breakdown of academic impact, for papers by Zachery R. Reichert Breakdown of academic impact, for papers by Zsófia Sztupinszki Breakdown of academic impact, for papers by W. Li Breakdown of academic impact, for papers by U. Matulonis Breakdown of academic impact, for papers by Theresa Link Breakdown of academic impact, for papers by Salvatore Luca Burgio Breakdown of academic impact, for papers by Dzifa Y. Duose Breakdown of academic impact, for papers by Frank Campana Breakdown of academic impact, for papers by Mikhail Dvorkin
Rankless by CCL
2026